Linoleoyl ethanolamide

Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1 (CB1) and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time[1][2].

Product Specifications

CAS Number

[68171-52-8]

Product Name Alternative

Linoleic acid monoethanolamide

UNSPSC

12352211

Hazard Statement

H225, H319

Target

Cannabinoid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/linoleoyl-ethanolamide.html

Purity

99.20

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCCCC/C=C\C/C=C\CCCCCCCC(NCCO)=O

Molecular Formula

C20H37NO2

Molecular Weight

323.51

Precautions

H225, H319

References & Citations

[1]Wang X, et al. X. Synthesis of linoleoyl ethanolamide. J Oleo Sci. 2013;62 (6) :427-433. |[2]Lin S, et al. Novel analogues of arachidonylethanolamide (anandamide) : affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41 (27) :5353-5361.